Drug intelligence / Profile preview

TMS-009

Development stage: Preclinical
Lead developer: TMS
Modality: Small Molecules
Administration: Oral

Overview

TMS-009 is a small molecule inhibitor of soluble epoxide hydrolase (sEH) currently in the preclinical stage of development by TMS Co., Ltd. Soluble epoxide hydrolase is an enzyme responsible for the metabolic degradation of epoxyeicosatrienoic acids (EETs), which are endogenous lipid mediators known for their anti-inflammatory, vasodilatory, and cardioprotective properties. By inhibiting sEH, TMS-009 aims to stabilize and increase the levels of EETs, potentially providing therapeutic benefits in a variety of conditions including inflammatory, cardiovascular, and metabolic diseases. The specific primary indication for TMS-009 has not yet been disclosed by the developer.

Targets

EPHX2 (Soluble epoxide hydrolase)

Beyond the preview

Go deeper on TMS-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TMS-009.

Explore the full profile